Advertisement

Clinical and Translational Oncology

, Volume 19, Issue 8, pp 976–988 | Cite as

Selection of DNA aptamers for extra cellular domain of human epidermal growth factor receptor 2 to detect HER2 positive carcinomas

  • A. Sett
  • B. B. Borthakur
  • U. BoraEmail author
Research Article

Abstract

Background

Human epidermal growth factor receptor 2 (Her2, an orphan receptor of ErbB family) is considered as an important biomarker as it plays a key role in the development and progression of aggressive types of breast, ovarian, stomach and gastric cancer. In the present study, we developed novel DNA aptamers against the extra-cellular domain (ECD) of Her2 protein for detection of Her2-positive carcinomas.

Methods

We cloned and expressed Her2–ECD protein in E. coli system. After purification, the protein was used as a bait for screening of specific DNA aptamer candidate from a pool of 1014–15 random oligonucleotides through in vitro Systematic Evaluation of Ligands by Exponential Enrichment (SELEX) process. The aptamer–protein binding kinetics was elucidated by isothermal calorimetry. The specificity of FAM-labelled ECD_Apt1 towards Her2-positive cell lines was estimated by FACS and immunofluorescence assay. The specificity of the candidate was also verified with the tissue samples of breast cancer patients by immunohistochemistry process.

Results

Among four selected candidates, ECD_Apt1 (having minimum ∆G = −3.24) showed the highest binding affinity (K d = 6.33 ± 0.86 nM) to Her2–ECD protein. The aptamer–protein sandwich assay showed a linear rise in chemiluminescence (at 490 nm wavelength) in the dynamic range of 100−700 nM ECD_Apt1 with a detection limit of 12.5 ± 2.5 ng/mL. Biotinylated ECD_Apt1 showed stronger cytoplasmic staining in Her2-positive breast cancer cell lines (SKBR3) compared to Her2-negative cells (MDA MB 231, MCF7). In paraffin-embedded breast cancer tissue sections, it showed specific and selective localization in the cytoplasmic niche of malignant duct cancer cells without any cross-reactivity to fibroblasts, inflammatory cells and adipocytes.

Conclusions

Binding assays, cytochemical and histochemical studies support ECD_Apt1 as a potential theranostic agent for Her2-positive carcinomas. ECD_Apt1 could be an effective low-cost alternative to conventional anti-Her2 antibody in solid phase immunoassays for cancer diagnosis and related applications.

Keywords

DNA aptamers HER2 Immunoassays Immunohistochemistry 

Notes

Acknowledgements

The authors would like to thank Department of Biotechnology, New Delhi, Govt. of India (Sanction order no: BT/CP/07/NE/TBP/2010 dt 28/03/2011) for providing financial support for this study. AS would like to thank IIT Guwahati and Ministry of Human Resource Development (MHRD), Government of India for fellowship.

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest however, a part of the work reported in the present article has been used to file an Indian patent application vide application number 715/KOL/2014.dated 30.06.2014.

Ethical approval and consent information

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was also obtained from all the patients included in the study.

References

  1. 1.
    Dean L. Pertuzumab therapy and ERBB2 (HER2) genotype drug. Pertuzumab. 2015;2:1–7.Google Scholar
  2. 2.
    Lenneman CG, Abdallah WM, Smith HM, Abramson V, Mayer IA, Silverstein C, et al. Sympathetic nervous system alterations with HER2+ antagonism: an early marker of cardiac dysfunction with breast cancer treatment? Ecancermedicalscience. 2014;8:446.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19(9):1523–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Amler L, Wang Y, Hampton G. HER2 as a Therapeutic target in ovarian cancer. Intechopen.Com [Internet]. 2010;10:1343–4.Google Scholar
  5. 5.
    Ferguson KM. A structure-based view of epidermal growth factor receptor regulation. Annu Rev Biophys [Internet]. 2008;37:353–73.CrossRefGoogle Scholar
  6. 6.
    Sliwkowski MX. Ready to partner. Nat Struct Biol. 2003;10:158–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Landgraf R. HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks. Breast Cancer Res. 2007;9:202.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-lin treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2003;20:719–26.CrossRefGoogle Scholar
  9. 9.
    Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science. 1990;249:505–10.CrossRefPubMedGoogle Scholar
  10. 10.
    Bora U, Sett A, Singh D. Nucleic acid based biosensors for clinical applications. Biosens J. 2013;1:104.Google Scholar
  11. 11.
    Jayasena SD. Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin Chem. 1999;45:1628–50.PubMedGoogle Scholar
  12. 12.
    Nonaka Y, Sode K, Ikebukuro K. Screening and improvement of an anti-VEGF DNA aptamer. Molecules [Internet]. 2010;15:215–25.CrossRefGoogle Scholar
  13. 13.
    Wilson R. Preparation of single-stranded DNA from PCR products with streptavidin magnetic beads. Nucleic Acid Ther [Internet]. 2011;21:437–40.CrossRefGoogle Scholar
  14. 14.
    Gopinath SCB. Methods developed for SELEX. Anal Bioanal Chem. 2007;387:171–82.CrossRefPubMedGoogle Scholar
  15. 15.
    Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res [Internet]. Oxford: Oxford University Press; 2003;31:3406–15.Google Scholar
  16. 16.
    Brown CJ, Dastidar SG, See HY, Coomber DW, Ortiz-Lombard AM, Verma C, et al. Rational design and biophysical characterization of thioredoxin-based aptamers: insights into peptide grafting. J Mol Biol Elsevier Ltd. 2010;395:871–83.CrossRefGoogle Scholar
  17. 17.
    Xu D, Chatakonda VK, Kourtidis A, Conklin DS, Shi H. In search of novel drug target sites on estrogen receptors using RNA aptamers. Nucleic Acid Ther. 2014;24(3):226–38.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Sosic A, Meneghello A, Cretaio E, Gatto B. Human thrombin detection through a sandwich aptamer microarray: interaction analysis in solution and in solid phase. Sens Mol Diver Preserv Int. 2011;11:9426–41.Google Scholar
  19. 19.
    Sett A, Borthakur BB, Sharma JD, Kataki AC, Bora U. DNA aptamer probes for detection of estrogen receptor α positive carcinomas. Transl Res. 2016. doi: 10.1016/j.trsl.2016.12.008.PubMedGoogle Scholar
  20. 20.
    Nicol C, Cesur Ö, Forrest S, Belyaeva TA, Bunka DHJ, Blair GE, et al. An RNA aptamer provides a novel approach for the induction of apoptosis by targeting the HPV16 E7 oncoprotein. PLoS One. 2013;8:e64781.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Scholl S, Beuzeboc P, Pouillart P. Targeting HER2 in other tumor types. Ann Oncol. 2001;12:44–50.CrossRefGoogle Scholar
  22. 22.
    Vinod BS, Nair HH, Vijayakurup V, Shabna A, Shah S, Krishna A, et al. Resveratrol chemosensitizes HER-2-overexpressing breast cancer cells to docetaxel chemoresistance by inhibiting docetaxel-mediated activation of HER-2–Akt axis. Cell Death Discov. 2015;1:15061.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Holstein CA, Chevalier A, Bennett S, Anderson CE, Keniston K, Olsen C, et al. Immobilizing affinity proteins to nitrocellulose: a toolbox for paper-based assay developers. Anal Bioanal Chem. 2016;408:1335–46.CrossRefPubMedGoogle Scholar
  24. 24.
    Pagano B, Mattia CA, Giancola C. Applications of isothermal titration calorimetry in biophysical studies of G-quadruplexes. Int J Mol Sci. 2009;10:2935–57.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Perozzo R, Folkers G, Scapozza L. Thermodynamics of protein-ligand interactions: history, presence, and future aspects. J Recept Signal Transduct Res. 2004;24:1–52.CrossRefPubMedGoogle Scholar
  26. 26.
    Kim MY, Jeong S. In vitro selection of RNA aptamer and specific targeting of ErbB2 in breast cancer cells. Nucleic Acid Ther. 2011;21:173–8.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Dastjerdi K, Tabar GH, Dehghani H, Haghparast A. Generation of an enriched pool of DNA aptamers for an HER2-overexpressing cell line selected by Cell SELEX. Biotechnol Appl Biochem. 2011;58:226–30.CrossRefPubMedGoogle Scholar
  28. 28.
    Liu Z, Duan J-H, Song Y-M, Ma J, Wang F-D, Lu X, et al. Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro. J Transl Med. 2012;10:148.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Xiang D, Zheng C, Zhou S-F, Qiao S, Tran PH-L, Pu C, et al. Superior performance of aptamer in tumor penetration over antibody: implication of aptamer-based theranostics in solid tumors. Theranostics (Ivyspring International Publisher). 2015;5:1083.CrossRefGoogle Scholar
  30. 30.
    Sun H, Zhu X, Lu PY, Rosato RR, Tan W, Zu Y. Oligonucleotide aptamers: new tools for targeted cancer therapy. Mol Ther Nucleic Acids. 2014;3:e182.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2017

Authors and Affiliations

  1. 1.Bioengineering Research Laboratory, Department of Biosciences and BioengineeringIndian Institute of Technology GuwahatiGuwahatiIndia
  2. 2.Department of Surgical OncologyDr. B. Borooah Cancer InstituteGuwahatiIndia
  3. 3.Mugagen Laboratories Pvt. Ltd., Technology Incubation CentreIndian Institute of Technology GuwahatiGuwahatiIndia

Personalised recommendations